TST002 not checked
Transcenta Therapeutics (Hangzhou) Co., Ltd.
FollowEvery change as it happens, and a Monday email
Trials
5 active
8 in total · 6 in the EU
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Postmenopausal Osteoporosis, Low Bone Mass
- Main trialPhase 2
- “This is a randomized, double-blind, placebo- and active-controlled Phase II study evaluating the efficacy and safety of TST002 injection (a humanized monoclonal antibody) in postmenopausal women with osteoporosis or low bone mass, aged 45-80 years. Approximately 110 participants will be randomized 1:1:1:1:1 (stratified by baseline BMD T-score) to one of five arms: TST002 400 mg every 8 weeks (Q8W), TST002 800 mg Q8W, TST002 1200 mg every 12 weeks (Q12W), placebo, or open-label denosumab 60 mg subcutaneously every 24 weeks. The study includes a screening period (Day -28 to Day -1), a main…”In the company’s words, NCT07806331 on ClinicalTrials.gov
Other drugs for Postmenopausal Osteoporosis
Coming up1
- 30 Apr 2027Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials8
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Not yet recruiting | 30 Apr 2027 | Study of TST002 Injection in Postmenopausal Women With Osteoporosis or Low Bone Mass | |
| Phase 1Unknown | 28 Apr 2023 | TST002 Intervenous Injection in Postmenopausal Women and Men With Reduced Bone Mineral Density | |
| Phase 3Authorised | not given | A Phase III double-blind placebo-controlled Randomised Trial of Aspirin on Recurrence and Survival in Colon Cancer Patients | |
| Phase 3Authorised | not given | A randomised, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of PQ Birch in subjects with seasonal allergic rhinitis and/or rhinoconjunctivitis induced by birch pollen exposure | |
| Phase 3/4Ended | not given | The effects of the manipulation of 5-HT, DA and NA on exercise-induced fatigue and brain activation | |
| Phase 2Not authorised | not given | A RAndomised Placebo Controlled Trial - to Explore the Efficacy and Mechanism of Action of Tezepelumab in EGPA- RACE-MATE | |
| Phase 2Authorised | not given | Tocotrienol and bevacizumab in metastatic colorectal cancer. A randomized phase II marker trial | |
| Phase 3Authorised | not given | Rifampin-free regimen versus rifampin-containing regimen in the treatment of staphylococcal prosthetic valve endocarditis: a multicenter randomized controlled non-inferiority study (RIFREE) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026